Danai Dima, MD^1,2, James A Davis, PharmD^2,3*, Nausheen Ahmed, MD^2,4, Aishwarya Sannareddy, MBBS^5*, Hira Shaikh, MBBS^2,6*, Zahra Mahmoudjafari, PharmD^2,4*, Jack Khouri, MD¹, Gurbakhash Kaur, MD, MA⁵, Christopher Strouse, MD^2,6, Jason Valent, MD¹, Larry D. Anderson Jr., MD, PhD⁵, Faiz Anwer, MD^1,2, Al-Ola Abdallah, MD^2,4 and Hamza Hashmi, MD^2,3*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
³Department of Hematology-Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
⁴Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS
⁵Division of Hematologic Malignancies and Cellular Therapy, Dept of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
⁶Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA

Darren Denjay Pan, MD¹, Tarek H. Mouhieddine, MD², Weijia Fu^3*, Erin Moshier^4*, Samir Parekh, MD¹, Sundar Jagannath, MD¹, Adriana C Rossi, MD, MSc¹, Hearn Jay Cho, MD⁵, Joshua Richter, MD², Larysa J Sanchez, MD¹, Santiago Thibaud, MD^1*, Cesar Rodriguez, MD^1* and Shambavi Richard, MD¹

¹Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
²Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
³Icahn School of Medicine at Mount Sinai, New York, NY
⁴Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, NY
⁵Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY

Junia Vieira dos Santos, MD, PhD^1*, David Melnekoff, MS^1*, Adolfo Aleman, MPA², Sherry Bhalla, PhD^3*, Tarek H. Mouhieddine, MD², Oliver Van Oekelen, MD, PhD², Sridevi Rajeeve, MD^4*, Bhaskar Upadhyaya, PhD^5*, Yogita Ghodke-Puranik, PhD^1*, Violetta Leshchenko, PhD^6*, Adeeb Rahman, PhD^7*, Shaked Afik, PhD^7*, Hadas Lewinsky, PhD^7*, Santiago Thibaud, MD^5*, Hearn Jay Cho, MD⁸, Joshua Richter, MD², Cesar Rodriguez, MD^5*, Larysa Sanchez, MD^2*, Adriana C Rossi, MD, MSc⁵, Shambavi Richard, MD⁵, Ajai Chari, MD^9*, Sundar Jagannath, MD¹⁰, Samir Parekh, MD⁵ and Alessandro Lagana, PhD⁶

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
³Mount Sinai Hospital, New York, NY
⁴Mount Sinai, New York, NY
⁵Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
⁶Icahn School of Medicine At Mount Sinai, New York, NY
⁷ImmunAI, New York, NY
⁸Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY
⁹at the time that the work was performed, Mount Sinai School of Medicine, New York, NY
¹⁰Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

Aintzane Zabaleta^1*, Noemi Puig, MD, PhD², Maria Teresa Cedena Romero, MD, PhD^3*, Jose J Perez^4*, Cristina Moreno^5*, Luis-Esteban Tamariz-Amador, MD^5*, Paula Rodriguez Otero, MD, PhD^6*, Veronica Gonzalez-Calle, MD, PhD^2*, Lucia Lopez Corral, MD, PhD^7*, Beatriz Rey-Búa^4*, Borja Puertas Martínez^4*, Fatima Miras^8*, Jose Sanchez-Pina^8*, Nieves Lopez^8*, Joaquin Martinez-Lopez, MD, PhD^8*, Maria Victoria Mateos, MD, PhD², Jesus San-Miguel, MD, PhD⁵ and Bruno Paiva^9*

¹CIMA (Pamplona)Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain
²Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
³Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
⁴Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain
⁵Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain
⁶Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain
⁷Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, Salamanca, Spain
⁸Hospital 12 de Octubre, Madrid, Spain
⁹Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain

Xiang Zhou^1*, Vivien Wagner^2*, Emilia Stanojkovska^3*, Christine Riedhammer^4*, Xianghui Xiao, MD^5*, Mara John^3*, Lukas Scheller^6*, Umair Munawar^7*, Seungbin Han^8*, Johannes M Waldschmidt, MD^9,10, Max S. Topp, MD^11*, Johannes Duell, MD^12*, Hermann Einsele, MD, PhD^5*, Angela Riedel, PhD^3*, Martin Kortüm, MD^13* and Leo Rasche, MD^5*

¹Department of Internal Medicine II, University Hospital Wuerzburg, WüRzburg, Germany
²University of Wurzburg, Wurzburg, Germany
³Mildred Scheel Early Career Center for Cancer Research, University Hospital Wurzburg, Wurzburg, Germany
⁴Department of Internal Medicine II, University Hospital Wuerzburg, Würzburg, Germany
⁵Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
⁶University Hospital Wurzburg, Wuerzbzrg, DEU
⁷Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
⁸University Hospital Wurzburg, Wuerzburg, DEU
⁹Department of Internal Medicine II, University of Wuerzburg Medical Center, Wuerzburg, Germany
¹⁰Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
¹¹Medizinische Klinik Und Poliklinik II Universitätsklinikum Wurzburg, Wurzburg, Germany
¹²Department of Internal Medicine II, Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany
¹³Mayo Clinic In Arizona, Scottsdale, AZ

Michel Delforge^1*, Krina K. Patel, MD, MSc², Laurie Eliason, MPH^3*, Devender Dhanda, PhD^3*, Ling Shi, PhD^4*, Shien Guo, PhD^4*, Thomas S. Marshall, PharmD^3*, Bertrand Arnulf, MD, PhD⁵, Michele Cavo, MD^6*, Ajay K. Nooka, MD, MPH⁷, Salomon Manier, MD, PhD⁸, Natalie S. Callander, MD⁹, Sergio A. Giralt, MD, FACP¹⁰, Hermann Einsele, MD, PhD^11*, Sikander Ailawadhi¹², Mihaela Popa-McKiver, MD, PhD^3*, Mark Cook, MBChB, PhD¹³ and Paula Rodriguez Otero, MD, PhD^14*

¹University Hospital Leuven, Leuven, Belgium
²The University of Texas MD Anderson Cancer Center, Houston, TX
³Bristol Myers Squibb, Princeton, NJ
⁴Evidera, Bethesda, MD
⁵Hôpital Saint-Louis, APHP, Université Paris cite, Paris, France
⁶Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
⁷Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
⁸Centre Hospitalier Universitaire de Lille, Lille, France
⁹University of Wisconsin Carbone Cancer Center, Madison, WI
¹⁰Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Medizinische Klinik und Poliklinik II, Uniklinikum Würzburg, Würzburg, Germany
¹²Mayo Clinic, Jacksonville, FL
¹³Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹⁴Clinica Universidad de Navarra, Pamplona, Spain